117309-47-4

Basic information

• Product Name: 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID
• Synonyms: 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID;2-{[(4-chlorophenyl)sulfonyl]amino}-2-phenylacetic acid (en);2-(4-ChlorophenylsulfonaMido)-2-phenylacetic acid;(2S)-2-[(4-chlorophenyl)sulfonylamino]-2-phenyl-acetic acid
• CAS NO: 117309-47-4
• Molecular Formula: C₁₄H₁₂ClNO₄S
• Molecular Weight: 325.77
• Mol File: 117309-47-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 175-177°C
• Boiling Point: 515.9°Cat760mmHg
• Flash Point: 265.8°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 1.81E-11mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID(117309-47-4)
• EPA Substance Registry System: 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID(117309-47-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 117309-47-4(Hazardous Substances Data)

Usage

General Description

2-([(4-chlorophenyl)sulfonyl]amino)-2-phenylacetic acid is a chemical compound that is commonly used in the pharmaceutical industry. It is a non-steroidal anti-inflammatory drug (NSAID) that is used to reduce pain and inflammation in conditions such as arthritis. It works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation. 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-2-PHENYLACETIC ACID is known for its potent analgesic and anti-inflammatory properties, and it has been found to be effective in the treatment of various types of pain and inflammation. Additionally, it is also being studied for its potential use in the treatment of certain types of cancer.

InChI:InChI=1/C14H12ClNO4S/c15-11-6-8-12(9-7-11)21(19,20)16-13(14(17)18)10-4-2-1-3-5-10/h1-9,13,16H,(H,17,18)/p-1/t13-/m1/s1

Upstream product

• 2935-35-5 (S)-2-phenylglycine 
• 98-60-2 4-chlorobenzenesulfonyl chloride 

Downstream Products

• 635291-25-7 4-Chloro-N-[(1S)-2-hydroxy-1-phenylethyl]benzenesulfonamide 

Relevant articles and documents

Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease

Novel multifunctional 3,6-Diphenyl-1,4-bis(phenylsulfonyl)piperazine-2,5-dione derivatives were designed and synthesized for the treatment of Alzheimer's disease (AD). The designed scaffold has blood brain barrier penetrating ability, acetylcholinesterase (AChE) and matrix metalloproteinase-2 (MMP-2) inhibition potential. Compounds 52 and 46 showed very significant inhibition against AChE, IC50 = 32.45 ± 0.044, 28.65 ± 0.029, BuChE, IC50 = 157.95 ± 0.264, 160.58 ± 0.082 and MMP-2, IC50 = 36.83 ± 0.015, 19.57 ± 0.005 (nM). In the enzyme kinetics study, lead molecule 46 showed non-competitive inhibition of AChE with Ki = 7 nM and competitive inhibition of MMP-2 with Ki = 20 nM. Compounds 52 and 46 inhibited AChE-induced Aβ aggregation at 20 μM. The compounds also exhibited in-vitro antioxidant potential in DPPH assay. Further, compound 46 was found to be a promising neuroprotective agent in MC65 cells. Lead molecule 46 significantly enhanced working memory in scopolamine induced amnesia animal model at dose of 5 mg/kg dose. The mitochondrial membrane potential was restored in animals when treated with compounds 52 and 46.

N- and 2-Substituted N-(Phenylsulfonyl)glycines as Inhibitors of Rat Lens Aldose Reductase

A variety of N-(phenylsulfonyl)-N-phenylglycines 5, N-(phenylsulfonyl)-2-phenylglycines 6, and N-(phenylsulfonyl)anthranilic acids 7 were prepared as analogues of the N-(phenylsulfonyl)glycine 1 aldose reductase inhibitors.In the rat lens assay, several derivatives of 5 display greater inhibitory activity than the corresponding glycines 1, suggesting that N-phenyl substitution enhances affinity for aldose reductase.Enzyme kinetic evaluations of the 4-benzoylamino analogues of 5 and 1 demonstrate that these compounds produce inhibition by the same mechanism.However, the significant differences in relative inhibitory potencies between compounds of series 5 and 1 may indicate that these compounds do not interact with the inhibitor binding site in precisely the same manner.Evaluation of the individual enantiomers of series 6 reveals that the S isomers are substantially more active than the corresponding R isomers.Also, with the exception of the naphthalene analogue 6n, the S stereoisomers of this series display greater inhibitory potencies than the glycines 1.The anthranilates 7 generally are less active than the glycines 1, demonstrating that direct incorporation of an aromatic ring in the glycine side chain may result in a decrease in affinity for aldose reductase.